A. Macdonald

Transplantation · 2001

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Who trusts A. Macdonald overall

1. Kdoqi Disclaimer
2. Philip F. Halloran
3. R. Marcén

Papers from A. Macdonald's perspective

Ordered by how strongly the researchers A. Macdonald trusts endorse each paper. Same corpus, a different order for every researcher.

1. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor (Nature Medicine)
2. Cancer after Kidney Transplantation in the United States (American Journal of Transplantation)
3. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (New England Journal of Medicine)

Their papers

• A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS (2001) — 622 citations